Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)

BACKGROUND: Primary systemic vasculitis (PSV) is a heterogeneous group of autoimmune conditions. There is an unmet need for alternative therapies that lead to sustained remission in patients with refractory disease. Alemtuzumab, an anti-CD52 antibody, depletes lymphocytes for prolonged periods and,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopaluni, Seerapani, Smith, Rona, Goymer, Donna, Cahill, Hugh, Broadhurst, Elizabeth, Wallin, Elizabeth, McClure, Mark, Chaudhry, Afzal, Jayne, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972754/
https://www.ncbi.nlm.nih.gov/pubmed/35365179
http://dx.doi.org/10.1186/s13075-022-02761-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972754/
https://www.ncbi.nlm.nih.gov/pubmed/35365179
http://dx.doi.org/10.1186/s13075-022-02761-6

Ejemplares similares